<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034019</url>
  </required_header>
  <id_info>
    <org_study_id>OTX-13-002</org_study_id>
    <nct_id>NCT02034019</nct_id>
  </id_info>
  <brief_title>Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone)
      depot when placed in the canaliculus of the eyelid for the treatment of post-surgical
      inflammation and pain in subjects who have undergone cataract extraction with intra-ocular
      lens implantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of Cells in Anterior Chamber of the Study Eye</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of Pain in Study Eye</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Post Ocular Surgical Inflammation and Pain</condition>
  <arm_group>
    <arm_group_label>OTX-DP (Dexamethasone Punctum Plug)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Resorbable hydrogel drug delivery vehicle containing dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVPP (Placebo Punctum Plug)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Resorbable hydrogel drug delivery vehicle containing no drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>OTX-DP (Dexamethasone Punctum Plug)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Punctum Plug</intervention_name>
    <arm_group_label>OTX-DP (Dexamethasone Punctum Plug)</arm_group_label>
    <arm_group_label>PVPP (Placebo Punctum Plug)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a cataract and is expected to undergo clear corneal cataract surgery with
             phacoemulsification and implantation of a posterior chamber intraocular lens

          -  Has a potential post-operative pinhole corrected Snellen VA of at least 20/200 or
             better in both eyes

        Exclusion Criteria:

          -  Any intraocular inflammation in the study eye present during the screening slit lamp
             examination

          -  Score greater than &quot;0&quot; on the Ocular Pain Assessment in the study eye at Screening

          -  Any intraocular inflammation in the study eye present during the screening slit lamp
             examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Project Manager</last_name>
    <role>Study Director</role>
    <affiliation>Ocular Therapeutix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texan Eye / Keystone Research, Ltd.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <results_first_submitted>February 29, 2016</results_first_submitted>
  <results_first_submitted_qc>January 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2020</results_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One subject inadvertently received PVPP instead of OTX-DP, as they had been randomized. This subject was followed safety but not included in the PP analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>OTX-DP (Dexamethasone Punctum Plug)</title>
          <description>Resorbable hydrogel drug delivery vehicle containing dexamethasone
Dexamethasone
Punctum Plug</description>
        </group>
        <group group_id="P2">
          <title>PVPP (Placebo Punctum Plug)</title>
          <description>Resorbable hydrogel drug delivery vehicle containing no drug
Punctum Plug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OTX-DP (Dexamethasone Punctum Plug)</title>
          <description>Resorbable hydrogel drug delivery vehicle containing dexamethasone
Dexamethasone
Punctum Plug</description>
        </group>
        <group group_id="B2">
          <title>PVPP (Placebo Punctum Plug)</title>
          <description>Resorbable hydrogel drug delivery vehicle containing no drug
Punctum Plug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="83"/>
            <count group_id="B3" value="247"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absence of Cells in Anterior Chamber of the Study Eye</title>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTX-DP (Dexamethasone Punctum Plug)</title>
            <description>Resorbable hydrogel drug delivery vehicle containing dexamethasone
Dexamethasone
Punctum Plug</description>
          </group>
          <group group_id="O2">
            <title>PVPP (Placebo Punctum Plug)</title>
            <description>Resorbable hydrogel drug delivery vehicle containing no drug
Punctum Plug</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Cells in Anterior Chamber of the Study Eye</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absence of Pain in Study Eye</title>
        <time_frame>Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTX-DP (Dexamethasone Punctum Plug)</title>
            <description>Resorbable hydrogel drug delivery vehicle containing dexamethasone
Dexamethasone
Punctum Plug</description>
          </group>
          <group group_id="O2">
            <title>PVPP (Placebo Punctum Plug)</title>
            <description>Resorbable hydrogel drug delivery vehicle containing no drug
Punctum Plug</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Pain in Study Eye</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>One subject was inadvertently treated with PVPP instead of OTX-TP, as they had been randomized. This subject was not included in the PP, but was followed for safety.</desc>
      <group_list>
        <group group_id="E1">
          <title>OTX-DP (Dexamethasone Punctum Plug)</title>
          <description>Resorbable hydrogel drug delivery vehicle containing dexamethasone
Dexamethasone
Punctum Plug</description>
        </group>
        <group group_id="E2">
          <title>PVPP (Placebo Punctum Plug)</title>
          <description>Resorbable hydrogel drug delivery vehicle containing no drug
Punctum Plug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>hypopyon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>inflammation</sub_title>
                <counts group_id="E1" events="47" subjects_affected="37" subjects_at_risk="162"/>
                <counts group_id="E2" events="38" subjects_affected="31" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Affairs</name_or_title>
      <organization>Ocular Therapeutix, Inc.</organization>
      <phone>781-357-4000</phone>
      <email>dmulani@ocutx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

